Literature DB >> 9494878

Disparate effects of out-patient cardiac and pulmonary rehabilitation programs on work efficiency and peak aerobic capacity in patients with coronary disease or severe obstructive pulmonary disease.

R V Milani1, C J Lavie.   

Abstract

BACKGROUND: Exercise intolerance is an integral component of chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD) and is caused by several mechanisms that ultimately impact overall functional capacity. We assessed various components of exercise function in patients with CHD and COPD during the course of cardiac and pulmonary rehabilitation to evaluate changes unique to each condition.
METHODS: Work efficiency (WEf, defined as delta watts/delta VO2) and peak VO2 were measured and compared at baseline and after 3 months (36 sessions) of outpatient cardiac and pulmonary rehabilitation programs in 25 patients (mean age = 66 +/- 7 years) with severe COPD (mean FEV1.0 = 0.90 +/- 0.35 L) and in 25 patients (mean age = 65 +/- 8 years) with CHD.
RESULTS: At baseline, patients with COPD had significantly reduced values of WEf (2.04 +/- 0.86 versus 3.23 +/- 1.38 watts/mL/kg/min; P = 0.004) and peak VO2 (13.2 +/- 3.9 versus 17.1 +/- 3.9 mL/kg/min; P = 0.005) compared with patients with CHD. After rehabilitation, patients with CHD increased peak VO2 by 12% (17.1 +/- 3.9 to 19.1 +/- 4.9 mL/kg/min; P = 0.01) with no change in WEf (3.23 +/- 1.38 to 3.32 +/- 1.43 watts/mL/kg/min; P = not significant). In contrast, patients with COPD increased peak VO2 by only 5% (13.2 +/- 3.9 to 13.9 +/- 3.8 mL/kg/min; P = 0.0008), but WEf increased by 36% (2.04 +/- 0.86 to 2.78 +/- 0.84 watts/mL/kg/min; P = 0.0002). Subjective measures of functional status improved similarly in both groups.
CONCLUSIONS: In contrast to patients with CHD, work inefficiency contributes significantly to exercise intolerance in patients with severe COPD. Outpatient rehabilitation programs enhance functional status in patients with CHD and COPD by differing mechanisms, depending on the underlying disease. These data show the disparate effects of out-patient rehabilitation on peak VO2 and WEf in cardiac and pulmonary patients.

Entities:  

Mesh:

Year:  1998        PMID: 9494878     DOI: 10.1097/00008483-199801000-00002

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil        ISSN: 0883-9212            Impact factor:   2.081


  6 in total

1.  Preventive cardiology and non-invasive cardiology research at the ochsner clinic foundation.

Authors:  Carl J Lavie; Richard V Milani; Yvonne Gilliland; J Alberto Bernal; Homeyar Dinshaw; Hector O Ventura
Journal:  Ochsner J       Date:  2006

2.  Cardiopulmonary Rehabilitation, Exercise Training, and Preventive Cardiology: An Overview of a Decade of Research at the Ochsner Heart and Vascular Institute: Presented in part at Grand Rounds, Research Series, Ochsner Medical Institutions, May 17, 1999.

Authors:  C J Lavie; R V Milani; M M Cassidy; Y E Gilliland; J A Bernal
Journal:  Ochsner J       Date:  1999-10

Review 3.  Rehabilitation in cardiac patients:what do we know about training modalities?

Authors:  Dominique Hansen; Paul Dendale; Jan Berger; Romain Meeusen
Journal:  Sports Med       Date:  2005       Impact factor: 11.928

4.  Comparison of cardiac rehabilitation outcomes in individuals with respiratory, cardiac or no comorbidities: A retrospective review.

Authors:  Mika L Nonoyama; Susan Marzolini R Kin; Dina Brooks; Paul Oh
Journal:  Can J Respir Ther       Date:  2016

5.  Comparison of the Effects of Cardiac Rehabilitation Between Obese and Non-obese Patients After Acute Myocardial Infarction.

Authors:  Seung-Kyu Lim; Jae-Young Han; Yu-Ri Choe
Journal:  Ann Rehabil Med       Date:  2016-10-31

Review 6.  Exercise Training in Patients with Chronic Respiratory Diseases: Are Cardiovascular Comorbidities and Outcomes Taken into Account?-A Systematic Review.

Authors:  Ana Machado; Kirsten Quadflieg; Ana Oliveira; Charly Keytsman; Alda Marques; Dominique Hansen; Chris Burtin
Journal:  J Clin Med       Date:  2019-09-13       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.